STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name of Reporting Person
Ciaramella Giuseppe

2. Issuer Name and Ticker or Trading Symbol
Beam Therapeutics Inc. [ BEAM ]

3. Date of Earliest Transaction (Month/Day/Year)
07/24/2023

4. If Amendment, Date of Original Filed (Month/Day/Year)
07/21/2023

5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
Director
X Officer (give title below)
President and CSO

6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person

Rule 10b5-1(c) Transaction Indication

Check this box if no longer subject to obligations may continue.

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>1. Title of Security (Instr. 3)</th>
<th>2. Transaction Date (Month/Day/Year)</th>
<th>3. Transaction Code (Instr. 1)</th>
<th>4. Securities Acquired (A) or Disposed Of (D) (Instr. 4 and 5)</th>
<th>5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>7. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>07/21/2023</td>
<td>M(1)</td>
<td>A (7)</td>
<td>181,728</td>
<td>D</td>
<td></td>
</tr>
<tr>
<td>Common Stock</td>
<td>07/21/2023</td>
<td>M(1)</td>
<td>A (7)</td>
<td>203,574</td>
<td>D</td>
<td></td>
</tr>
<tr>
<td>Common Stock</td>
<td>07/21/2023</td>
<td>M(1)</td>
<td>D (7)</td>
<td>48,250</td>
<td>D</td>
<td></td>
</tr>
<tr>
<td>Common Stock</td>
<td>07/24/2023</td>
<td>M(1)</td>
<td>A (7)</td>
<td>49,456</td>
<td>D</td>
<td></td>
</tr>
<tr>
<td>Common Stock</td>
<td>07/24/2023</td>
<td>M(1)</td>
<td>D (7)</td>
<td>48,250</td>
<td>D</td>
<td></td>
</tr>
</tbody>
</table>

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>1. Title of Derivative Security (Instr. 3)</th>
<th>2. Conversion or Exercise Price of Derivative Security</th>
<th>3. Transaction Date (Month/Day/Year)</th>
<th>3A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>4. Transaction Code (Instr. 1)</th>
<th>5. Number of Derivative Securities Acquired (A) or Disposed Of (D) (Instr. 4 and 5)</th>
<th>6. Date Exercisable and Expiration Date (Month/Day/Year)</th>
<th>7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)</th>
<th>8. Price of Derivative Security (Instr. 5)</th>
<th>9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)</th>
<th>10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>11. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock Option (Right to Buy)</td>
<td>$7.22</td>
<td>07/21/2023</td>
<td>M(1)</td>
<td>69,438</td>
<td>A (1)</td>
<td>05/17/2029 Common Stock 69,438 (A)</td>
<td>$7.22</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stock Option (Right to Buy)</td>
<td>$7.22</td>
<td>07/21/2023</td>
<td>M(1)</td>
<td>21,846</td>
<td>A (1)</td>
<td>05/31/2029 Common Stock 21,846 (A)</td>
<td>$7.22</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stock Option (Right to Buy)</td>
<td>$7.22</td>
<td>07/24/2023</td>
<td>M(1)</td>
<td>1,206</td>
<td>A (1)</td>
<td>05/17/2029 Common Stock 1,206 (A)</td>
<td>$7.22</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Explanation of Responses:

1. The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.
2. These shares of Common Stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $32.00 to $32.11, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $32.00 to $32.895, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
5. This stock option vests as to 25% on the first anniversary of the vesting commencement date, October 1, 2019, and at a rate of 2.78% each month thereafter until the option is fully vested.

By: /s/ Christine Bellon
Attorney-in-fact 07/25/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.